(Total Views: 443)
Posted On: 05/19/2019 10:09:07 AM
Post# of 333
Dr. Pestel hypothesizes that CCR5 tropism present in 20-30% of all cancer patients is the driving mechanism behind metastasis.
Current CYDY mTNBC trial ( ttps://clinicaltrials.gov/ct2/show/NCT03838367 ) in the trial criteria section requires to demonstrate CCR5 tropism based on the cancer biopsy sample.
For a treatment-experienced patient with an ovarian cancer without a saved biopsy, is there a blood-based CCR5 tropism test of CTCs that may be ovarian cancer specific or cancer type agnostic?
This test still in development could extract all types of CTC in the blood - https://news.uga.edu/scientists-develop-techn...mor-cells/ . But, one still would need to perform a CCR5 tropism test of the extracted CTCs.
Could CCR5 occupancy test be used for this purpose?
Any suggestions would be greatly appreciated.
Current CYDY mTNBC trial ( ttps://clinicaltrials.gov/ct2/show/NCT03838367 ) in the trial criteria section requires to demonstrate CCR5 tropism based on the cancer biopsy sample.
For a treatment-experienced patient with an ovarian cancer without a saved biopsy, is there a blood-based CCR5 tropism test of CTCs that may be ovarian cancer specific or cancer type agnostic?
This test still in development could extract all types of CTC in the blood - https://news.uga.edu/scientists-develop-techn...mor-cells/ . But, one still would need to perform a CCR5 tropism test of the extracted CTCs.
Could CCR5 occupancy test be used for this purpose?
Any suggestions would be greatly appreciated.
(0)
(0)
